Parameter
| Biomarker | CD163, CD206, versican | Full name | Cluster of Differentiation 163、Cluster of Differentiation 206 | Molecular Type | protein/nucleic acid |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | prognosis, microenvironment assessment | ||
| Disease | Multiple Myeloma (MM) | Disease Subtypes | / | ||
| Organ | Bone marrow, Serum | Test Sample / Technology Platform | serum、marrow | ||
| Pathobiological Mechanisms | Tumor-derived extracellular vesicles carry immunosuppressive molecules and regulate the microenvironment; versican promotes adhesion and angiogenesis. | ||||
| Clinical Availability Status | Frontier research phase | ||||
| Notes and Dynamics | miR-203 and miR-30d in EVs can be used for early diagnosis; Versican promotes tumor growth through FAK/STAT3 pathway, and its inhibitor combined with lenalidomide shows synergistic effect. | ||||